Porcine coronavirus vaccines

Abstract

The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.

What is claimed is: 
     
         1 . An immunogenic composition comprising an antigen of a porcine epidemic diarrhea virus (PEDV) and an adjuvant, wherein the PEDV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 32 or 36; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 29 or 33; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 30, 34, 46, or 52. 
     
     
         2 . The immunogenic composition of  claim 1 , wherein the antigen is a chemically inactivated whole PEDV. 
     
     
         3 . The immunogenic composition of  claim 1 , wherein the antigen is a whole PEDV chemically inactivated with ethylenimine, binary ethylenimine, acetylethylenimine, or any combinations thereof. 
     
     
         4 . The immunogenic composition of  claim 1 , wherein the antigen is a recombinant antigen. 
     
     
         5 . The immunogenic composition of  claim 4 , wherein the recombinant antigen comprises:
 (i) a PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53; and/or (ii) a polynucleotide encoding the PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53.   
     
     
         6 . The immunogenic composition of  claim 4 , wherein the recombinant antigen comprises a M, E, or N protein of PEDV. 
     
     
         7 . The immunogenic composition of  claim 4 , wherein the recombinant antigen is a recombinant vector, a recombinant PEDV spike protein, or a combination thereof. 
     
     
         8 . The immunogenic composition of  claim 1 , wherein the adjuvant is an oil-in-water emulsion. 
     
     
         9 . The immunogenic composition of  claim 1 , further comprising a pharmaceutically acceptable carrier and/or an excipient. 
     
     
         10 . The immunogenic composition of  claim 1 , further comprising an antigen of a porcine  Deltacoronavirus  (PDCoV). 
     
     
         11 . The immunogenic composition of  claim 10 , wherein the PDCoV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 2, 6, or 10; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 1, 5, or 9; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 3, 7, 11, 17, or 27. 
     
     
         12 . The immunogenic composition of  claim 11 , wherein the antigen of the PDCoV is an inactivated whole PDCoV. 
     
     
         13 . The immunogenic composition of  claim 11 , wherein the antigen of the PDCoV is a recombinant antigen comprising: (i) a PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28; and/or (ii) a polynucleotide encoding the PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28. 
     
     
         14 . A method for reducing a pig's risk for developing clinical signs of disease associated with PEDV, comprising administering to the pig the immunogenic composition according to  claim 1 . 
     
     
         15 . A method for reducing a pig's risk for developing clinical signs of disease associated with PEDV, comprising administering to the pig the immunogenic composition according to  claim 11 , and wherein the method reduces the pig's risk for developing clinical signs of disease associated with PEDV and PDCoV. 
     
     
         16 . A method for producing an immunogenic composition comprising a recombinant antigen of a PEDV and an adjuvant, comprising:
 producing the recombinant antigen in a host cell;   harvesting the recombinant antigen from the host cell; and   adding an oil-in-water emulsion-based adjuvant to the recombinant antigen,   wherein the recombinant antigen comprises: (i) a PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53; and/or (ii) a polynucleotide encoding the PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53.   
     
     
         17 . The method of  claim 16 , wherein the recombinant antigen comprises a PEDV spike protein expressed by a recombinant baculovirus vector. 
     
     
         18 . The method of  claim 17 , wherein the host cell is an insect cell. 
     
     
         19 . An immunogenic composition comprising an antigen of a PDCoV and an adjuvant, wherein the PDCoV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 2, 6, or 10; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 1, 5, or 9; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 3, 7, 11, 17, or 27. 
     
     
         20 . The immunogenic composition of  claim 19 , wherein the antigen is:
 an inactivated whole PDCoV; or   a recombinant antigen comprising: (i) a PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28; and/or (ii) a polynucleotide encoding the PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28.